

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 855.889.2946

Patient Name: _____ DOB: _____ Phone: _____

Patient Status: New to Therapy Continuing Therapy **Next Treatment Date:** _____

MEDICAL INFORMATION

Diagnosis: Ulcerative Colitis (UC) Other: _____

ICD-10 Code: _____

Patient weight: _____ lbs. Allergies: _____

THERAPY ORDER

Tremfya (guselkumab) IV loading dose for UC:

200mg IV at week 0, 4, and 8

Tremfya (guselkumab) maintenance subQ for UC (to be filled by Paragon Specialty Pharmacy):

100mg subQ at week 16, then every 8 weeks thereafter x1 year

200mg subQ at week 12, then every 4 weeks thereafter x1 year

Lab Orders: _____ **Frequency:** Every infusion Other: _____
 Perform TB QFT testing yearly (optional)

Required labs to be drawn by: Infusion Center Referring Provider

Other orders: _____

Home IV Biologic Ana-kit Orders (adult):

- Epinephrine: >30kg (>66lbs): EpiPen 0.3mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1
- Diphenhydramine: Administer 25-50mg orally OR IV (adult)
- NS 0.9% 1000mL IV bolus per protocol PRN (adult)

Home biologic injection Ana-kit (adult):

- Dispense per protocol EpiPen 0.3mg IM (2-pack)

Refer to physician order or institutional protocol for pediatric dosing Ana-kit

Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

PROVIDER INFORMATION

By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: _____ Signature: _____ Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

Opt out of Paragon selecting site of care (if checked, please list site of care): _____

PREFERRED LOCATION

City: _____ State: _____

View our locations here:





COMPREHENSIVE SUPPORT FOR TREMFYA (GUSELKUMAB) THERAPY

PATIENT INFORMATION:

Patient Name: _____ DOB: _____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
 - Has the patient had a documented contraindication/intolerance or failed trial of a corticosteroid or immunomodulator? Yes No
If yes, which drug(s)? _____
 - Does the patient have a contraindication/intolerance or failed trial any biologic (i.e., Humira, Stelara, Cimzia, infliximab)? Yes No
If yes, which drug(s)? _____
- Include labs and/or test results to support diagnosis
- If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching biologic therapies, please perform a wash-out period of _____ weeks prior to starting Tremfya.
- Other medical necessity: _____

REQUIRED PRE-SCREENING

- TB screening test (completed within 12 months for new start) - attach results**
 - Positive** **Negative**

*If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.